Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Non-Current Assets (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Non-Current Assets for 6 consecutive years, with $22.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 16.32% year-over-year to $22.6 million, compared with a TTM value of -$390.8 million through Dec 2025, changed 0.2%, and an annual FY2025 reading of $22.6 million, down 16.32% over the prior year.
  • Non-Current Assets was $22.6 million for Q4 2025 at Keros Therapeutics, down from $27.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $27.0 million in Q4 2024 and bottomed at -$463.1 million in Q1 2024.
  • Average Non-Current Assets over 5 years is -$60.4 million, with a median of $6.7 million recorded in 2022.
  • The sharpest move saw Non-Current Assets skyrocketed 451.4% in 2022, then fell 16.32% in 2025.
  • Year by year, Non-Current Assets stood at $3.8 million in 2021, then surged by 451.4% to $21.0 million in 2022, then rose by 8.18% to $22.7 million in 2023, then increased by 18.74% to $27.0 million in 2024, then dropped by 16.32% to $22.6 million in 2025.
  • Business Quant data shows Non-Current Assets for KROS at $22.6 million in Q4 2025, $27.0 million in Q4 2024, and -$463.1 million in Q1 2024.